Results 291 to 300 of about 1,888,881 (401)

PEP-R619W Distinctly Modulates Persistent Type-I Interferon Signaling to enhance DC and CD8 T cell function 4147 [PDF]

Anam Fatima Shaikh, Jenna Barnes, Tammy Cockerham, Nancy Schwarting, Robin C. Orozco   +4 more
openalex   +1 more source

TRIM38 Suppresses Breast Cancer Progression via Modulating SQSTM1 Ubiquitination and Autophagic Flux

Advanced Science, EarlyView.
TRIM38, an E3 ubiquitin ligase, suppresses breast cancer progression by inhibiting proliferation, migration, and invasion. Downregulated in breast tumor, its loss correlates with poor prognosis. Mechanistically, TRIM38 mediates K63‐linked ubiquitination of SQSTM1/p62 at K420, disrupting SQSTM1‐LC3 interaction and blocking autophagic flux.
Shan Jiang, Lijuan Wang, Dianwen Han, Peng Su, Bing Chen, Wenjing Zhao, Tong Chen, Ning Zhang, Xiaolong Wang, Yiran Liang, Yaming Li, Chen Li, Xi Chen, Dan Luo, Qifeng Yang   +14 more
wiley   +1 more source

ADAR1-Mediated RNA Editing Regulates Innate Immunity in Pulmonary Hypertension. [PDF]

Circ Res
Shen Y, Bisserier M.
europepmc   +1 more source

Type I Interferons Produced by Resident Renal Cells May Promote End-Organ Disease in Autoantibody-Mediated Glomerulonephritis

, 2009
Anna‐Marie Fairhurst, Chun Xie, Yuyang Fu, Andrew Wang, Christopher Boudreaux, Xin Zhou, Ricardo Cibotti, Anthony J. Coyle, John E. Connolly, Edward K. Wakeland, Chandra Mohan   +10 more
openalex   +1 more source

Disrupting the Formation of YAP Condensates Promotes the Activation of AMPKα to Inhibit the Progression of Primary Liver Cancer

Advanced Science, EarlyView.
This study systematically investigates the function and molecular mechanisms of YAP phase separation in multiple primary liver cancers. These findings provide novel insights into phase separation‐mediated primary liver cancer development and validate targeted disruption of this process as an effective therapeutic strategy for primary liver cancer ...
Shuang‐Zhou Peng, Jia‐Jia Liang, Yun‐Feng Zhan, Wei‐Xun Wu, Wan‐Li Xu, Xiao‐Kun Zhang, Li‐Jun Cai, Fu‐Quan Jiang   +7 more
wiley   +1 more source

Type I Interferon Gene Expression and Its Association With Ocular Involvement in Systemic Lupus Erythematosus. [PDF]

ACR Open Rheumatol
Costa RT, Guaraná WL, da Silva Júnior BM, Clementino J, Inês LS, Sandrin-Garcia P, Fragoso TS.   +6 more
europepmc   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science, EarlyView.
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
wiley   +1 more source

Context-Specific Diversity of Antimicrobial Functions of Interferon-Stimulated Genes. [PDF]

Viruses
Harioudh MK, Sarkar SN.
europepmc   +1 more source

Host‐Directed Antiviral Activity of SB2960 Through Selective Induction and Remodeling of Stress Granules

Advanced Science, EarlyView.
Amid the ongoing threat of emerging viral pathogens, host‐directed antivirals offer a strategy to overcome viral mutation and drug resistance. SB2960, a small‐molecule inducer of stress granules (SGs), exhibits potent broad‐spectrum antiviral activity with minimal cytotoxicity.
Wan Gi Byun, Sumin Son, JinAh Lee, Minha Lee, Meehyun Ko, Songrui Zhao, Ju Hee Kim, Kannan Vaithegi, Ji Hoon Kwon, Jung Ho Lee, Sangeun Jeon, Dawon Yi, Peng Zou, Seungtaek Kim, Seung Bum Park   +14 more
wiley   +1 more source

Proteogenomic Characterization Reveals Subtype‐Specific Therapeutic Potential for HER2‐Low Breast Cancer

Advanced Science, EarlyView.
Multiomic profiling of HER2‐low breast cancer identifies three proteomic subtypes with distinct therapeutic strategies: endocrine, antiangiogenic, and anti‐HER2 therapies. Genomic and lactate modification landscapes are detailed, providing insights for precise management.
Shouping Xu, Keda Yu, Lei Liu, Qin Wang, Xiaohui Wu, Yihai Chen, Guozheng Li, Xin Zhang, Bo Wei, Zitong Fu, Abiyasi Nanding, Zuxianglan Zhao, Lingbing Yang, Xingda Zhang, Jianyu Wang, Wantong Sun, Yi Hao, Zhongyi Cheng, Xiaojiang Cui, Hao Wu, Da Pang   +20 more
wiley   +1 more source